All Cell Therapies > Cell Therapy Card
Sign in for full access

Bone marrow-derived progenitor cells for myocardial infarction

The aim of this study is to determine the safety of intra-coronary infusion of CD133+ cell-enriched, bone marrow-derived, autologous progenitor cells, 5-10 days after acute percutaneous coronary revascularization in myocardial infarction (MI) patients.

In previous clinical trials, it was found that treatment of myocardial infarction (MI) patients by intracoronary administration of 12.6±2.2×10^6 a cell suspension enriched with CD133+ cells is feasible but was associated with increased incidence of coronary events. Nevertheless, it seemed to be associated with improved left ventricular performance, which paralleled increased myocardial perfusion and viability. In patients treated <7 days following MI, there was accelerated luminal loss and reduced conductance of the infarct-related artery.
See additional Cell Therapies for: Heart
Bone marrow-derived progenitor cells for myocardial infarction